Resources
AVAC’s Resource Database contains educational and advocacy materials covering a wide range of issues on biomedical prevention of HIV, STIs, COVID-19 and emerging health threats—from research to rollout.
To search for clinical trials and detailed information on products in development, visit our Prevention Research & Development Database
Results
showing 1-10 of 528
Spotlight on MPTs Addressing STIs
This graphic outlines the development journey of multipurpose technologies (MPTs) that guard against STIs, including HIV, while also preventing pregnancy. It tracks the advancement of various potential products through different trial stages, emphasizing their combined protective roles.
Prevention Option:
MPT R&D Funding 2018-2021
This graphic tracks funding levels for a variety of multipurpose technologies for several years.
Prevention Option:
At A Glance: The MPT R&D Pipeline
This graphic shows the status of products in development.
Prevention Option:
Advocates’ Guide to Multipurpose Prevention Technologies (MPTs)
Multipurpose prevention technologies (MPTs) are products designed to simultaneously address more than one sexual and reproductive health concern. This advocates’ guide shows the pipeline of products in development, discusses why MPTs are needed, investment, and what advocates can do to push for MPT development and introduction.
Prevention Option:
The Future of ARV-Based Prevention and More
The pipeline of non-vaccine HIV prevention products includes oral pills, vaginal rings, vaginal and rectal gels, vaginal films, long-acting injectable antiretrovirals and more. Also pictured are the range of MPTs in development that aim to reduce the risk of HIV and STIs and/or provide effective contraception for women.
Prevention Option:
The Lens on LEN
In late June 2024, Gilead Sciences announced an early review of the data of the PURPOSE 1 trial by an
independent monitoring board, which found that injectable lenacapavir (LEN) provided as prevention
was safe and highly effective against HIV. No infections were seen among trial participants those receiving LEN. This advocates’ primer provides further background on the product and trials, raises key questions, and explores next steps.
Prevention Option:
An Overview of Lenacapavir for PrEP Trials
The PURPOSE trials evaluate the safety and efficacy of injectable lenacapavir (LEN), an investigational antiretroviral (ARV) drug being studied as a potential PrEP product. This graphic shows the latest status of all five trials including the groundbreaking results of PURPOSE 1.
Prevention Option:
Advocates’ Guide to Doxycycline to Prevent Bacterial STIs (DoxyPEP)
DoxyPEP is a post-exposure prophylaxis used to prevent the acquisition of some bacterial STIs after sex. DoxyPEP is inexpensive, easily tolerated, and widely available. However, questions remain regarding who will benefit most from DoxyPEP and how to implement this strategy broadly to ensure equitable access.
Years Ahead in HIV Prevention Research: Time to Market
This timeline shows the potential time points when the next-generation of HIV prevention options might find their way into new programs.
Prevention Option:
New Product Introduction Update
A graphic showing ongoing studies of injectable cabotegravir and the dapivirine vaginal ring in eastern and southern Africa.
showing 1-10 of 528